ERBB2 and breast carcinoma: Low amounts of common antigens investigated for breast cancer, including HER2, MUC1, and EGFR, are also present in normal tissues, raising the possibility of unintentional CAR-T-cell activation and toxicities such “on-target, off-tumor” consequences.